

=> file caplus wpids uspatfull biosis medline embase

FILE 'CAPLUS' ENTERED AT 16:11:44 ON 19 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:11:44 ON 19 MAY 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 16:11:44 ON 19 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:11:44 ON 19 MAY 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 16:11:44 ON 19 MAY 2002

FILE 'EMBASE' ENTERED AT 16:11:44 ON 19 MAY 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> d his

(FILE 'HOME' ENTERED AT 16:07:34 ON 19 MAY 2002)

FILE 'CAPLUS, WPIDS, USPATFULL, BIOSIS, MEDLINE, EMBASE' ENTERED AT
16:11:44 ON 19 MAY 2002

L1 145055 (REDUC? OR PREVENT?) (P)ADHESION
L2 120 S L1(P)(BODY CAVITY)
L3 9 S L2 AND (DEXTRIN OR POLYDEXTRIN)

=> d l3 1-9 ibib ab

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:736520 CAPLUS
DOCUMENT NUMBER: 131:342041
TITLE: **Dextrin**-containing composition for
preventing surgical adhesions
INVENTOR(S): Brown, Colin
PATENT ASSIGNEE(S): ML Laboratories PLC, UK
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958168	A1	19991118	WO 1999-GB1306	19990513
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9938336	A1	19991129	AU 1999-38336	19990513

AU 740832 B2 20011115
 BR 9911769 A 20010206 BR 1999-11769 19990513
 EP 1085920 A1 20010328 EP 1999-920952 19990513
 EP 1085920 B1 20011219

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

AT 211002 E 20020115 AT 1999-920952 19990513
 ES 2165735 T3 20020316 ES 1999-920952 19990513
 NO 2000005492 A 20010112 NO 2000-5492 20001101

PRIORITY APPLN. INFO.:

GB 1998-10127 A 19980513
 US 1999-272713 A 19990319
 WO 1999-GB1306 W 19990513

AB A method of **preventing** or **reducing** the incidence of post-operative **adhesions** in or assocd. with a **body cavity**, comprises introducing into the **body cavity** a compn. contg. an aq. soln. or suspension or gel formulation contg. polysaccharide **dextrin**. Preferably, the compn. is allowed to remain in the **body cavity** for a min. of 2-3 days and esp. over the period during which fibrin exudation is at a max.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 2 OF 9 WPIDS (C) 2002 THOMSON DERWENT
 ACCESSION NUMBER: 2001-589646 [66] WPIDS
 DOC. NO. CPI: C2001-174785
 TITLE: Composition used for treating adhesions formed as result of inflammatory response e.g. chronic inflammatory conditions comprises aqueous formulation of polysaccharide **dextrin**.
 DERWENT CLASS: A96 B04
 INVENTOR(S): CONROY, S
 PATENT ASSIGNEE(S): (MLML-N) ML LAB PLC
 COUNTRY COUNT: 94
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001052866	A1	20010726	(200166)*	EN	30
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001026926	A	20010731	(200171)		
GB 2363713	A	20020109	(200211)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001052866	A1	WO 2001-GB193	20010119
AU 2001026926	A	AU 2001-26926	20010119
GB 2363713	A	GB 2000-15035	20000621

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 2001026926	A Based on	WO 200152866

PRIORITY APPLN. INFO: GB 2000-15035 20000621; GB 2000-1352
20000121

AB WO 200152866 A UPAB: 20011113

NOVELTY - Composition comprises an aqueous formulation containing a polysaccharide **dextrin**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a biocompatible, bioresorbable, non-toxic **adhesion prevention** kit for **preventing** or **reducing** the incidence of **adhesions** in mammals comprises the aqueous formulation; and

(2) products containing the aqueous formulation as a combined preparation for **preventing** or **reducing** the incidence of **adhesions**.

USE - Used for the treatment of **adhesions** formed as a result of an inflammatory response, other than post-operative **adhesions**, and for **preventing** or **reducing** the incidence or **adhesions** in or associated with a **body cavity** such as peritoneum, pericardium or plura and synovial cavities such as joints and tendons in humans or animals. The inflammatory response includes chronic inflammatory conditions such as pelvic inflammatory disease, arthritis, chronic inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome and/or acute inflammatory conditions such as those induced by tissue injury, which is as a result of chemical insult.

ADVANTAGE - The composition has a good shelf life. The **dextrin** is non-toxic, cheap and holds fluid in a **body cavity** and can also be readily metabolized within the body. It does not provide any undesired side effects or dependency.
Dwg.0/3

L3 ANSWER 3 OF 9 WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: 2000-038967 [03] WPIDS
DOC. NO. NON-CPI: N2000-029373
DOC. NO. CPI: C2000-010069
TITLE: **Prevention or reduction of surgical adhesions in body cavities.**
DERWENT CLASS: B04 D22 P34
INVENTOR(S): BROWN, C
PATENT ASSIGNEE(S): (MLML-N) ML LAB PLC
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9958168	A1	19991118	(200003)*	EN	29
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG US UZ VN YU ZA ZW					
AU 9938336	A	19991129	(200018)		
BR 9911769	A	20010206	(200111)		

NO 2000005492 A 20010112 (200115)
 EP 1085920 A1 20010328 (200118) EN
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 CN 1300226 A 20010620 (200159)
 AU 740832 B 20011115 (200202)
 EP 1085920 B1 20011219 (200206) EN
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 DE 69900648 E 20020131 (200216)
 ES 2165735 T3 20020316 (200227)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9958168	A1	WO 1999-GB1306	19990513
AU 9938336	A	AU 1999-38336	19990513
BR 9911769	A	BR 1999-11769	19990513
		WO 1999-GB1306	19990513
NO 2000005492	A	WO 1999-GB1306	19990513
		NO 2000-5492	20001101
EP 1085920	A1	EP 1999-920952	19990513
		WO 1999-GB1306	19990513
CN 1300226	A	CN 1999-806083	19990513
AU 740832	B	AU 1999-38336	19990513
EP 1085920	B1	EP 1999-920952	19990513
		WO 1999-GB1306	19990513
DE 69900648	E	DE 1999-600648	19990513
		EP 1999-920952	19990513
		WO 1999-GB1306	19990513
ES 2165735	T3	EP 1999-920952	19990513

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9938336	A Based on	WO 9958168
BR 9911769	A Based on	WO 9958168
EP 1085920	A1 Based on	WO 9958168
AU 740832	B Previous Publ.	AU 9938336
	Based on	WO 9958168
EP 1085920	B1 Based on	WO 9958168
DE 69900648	E Based on	EP 1085920
	Based on	WO 9958168
ES 2165735	T3 Based on	EP 1085920

PRIORITY APPLN. INFO: US 1999-272713 19990319; GB 1998-10127
 19980513

AB WO 9958168 A UPAB: 20000118

NOVELTY - Composition containing the polysaccharide **dextrin** in an aqueous formulation to **prevent** or **reduce** the incidence of post-operative **adhesions** in or associated with a **body cavity**.

USE - The product is used as stated, to **prevent** or **reduce** the risk of post-operative **adhesions** in **body cavities**, including the peritoneum, pericardium, pleura, and synovial cavities for joints and tendons, notably the peritoneum, also for possible **adhesions** after spinal and cranial surgery. For these purposes, the product is conveniently packaged as a

kit

for surgical use in humans (or other animals) containing the

dextrin or derivative as a solution, suspension, or gel.

ADVANTAGE - The **dextrin** is easily water soluble, with good biocompatibility, is metabolizable, and does not cause immunological hypersensitivity, in contrast to prior art dextran used for these purposes. The method is also superior to patch application in the form of films.

Dwg.0/0

L3 ANSWER 4 OF 9 USPATFULL

ACCESSION NUMBER: 2000:141902 USPATFULL
TITLE: Medical uses of in situ formed gels
INVENTOR(S): Viegas, Tacey X., Birmingham, AL, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., St. Clair Shores, MI, United States
PATENT ASSIGNEE(S): MDV Technologies, Inc., San Diego, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6136334		20001024
APPLICATION INFO.:	US 1999-330618		19990611 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-773755, filed on 23 Dec 1996, now patented, Pat. No. US 5958443 which is a continuation of Ser. No. US 1993-174101, filed on 28 Dec 1993, now abandoned which is a continuation of		
Ser.	No. US 1991-785305, filed on 30 Oct 1991, now		
patented,	Pat. No. US 5318780		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro, LLPW. Patrick BengtssonNan Wu		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1137		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical **body cavity** or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of **preventing adhesions**.

L3 ANSWER 5 OF 9 USPATFULL

ACCESSION NUMBER: 1999:117015 USPATFULL
TITLE: Medical uses of in situ formed gels
INVENTOR(S): Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United States
PATENT ASSIGNEE(S): MDV Technologies, Inc., San Diego, CA, United States
(U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5958443 19990928
APPLICATION INFO.: US 1996-773755 19961223 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-174101, filed on 28
Dec 1993, now patented, Pat. No. US 5587175 which is a
continuation of Ser. No. US 1991-785305, filed on 30
Oct 1991, now patented, Pat. No. US 5318780
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Azpuru, Carlos A.
LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro LLP
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 1248

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal
vehicles for drug delivery. They are especially suited for topical
body cavity or injection application of drugs or
diagnostic agents; for drug or diagnostic agent delivery to the eye of
a
mammal; as protective corneal shields; or as ablatable corneal masks
useful in laser reprofiling of the cornea. The compositions without the
addition of a drug or diagnostic agent are useful as medical devices,
for instance, in separating surgically or otherwise injured tissue as a
means of **preventing adhesions**.

L3 ANSWER 6 OF 9 USPATFULL

ACCESSION NUMBER: 96:118391 USPATFULL
TITLE: Medical uses of in situ formed gels
INVENTOR(S): Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United
States
PATENT ASSIGNEE(S): MDV Technologies, Inc., Dearborn, MI, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5587175		19961224
APPLICATION INFO.:	US 1993-174101		19931228 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-785305, filed on 30 Oct 1991, now patented, Pat. No. US 5318780		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1104		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal
vehicles for drug delivery. They are especially suited for topical
body cavity or injection application of drugs or
diagnostic agents; for drug or diagnostic agent delivery to the eye of
a
mammal; as protective corneal shields; or as ablatable corneal masks
useful in laser reprofiling of the cornea. The compositions without the
addition of a drug or diagnostic agent are useful as medical devices,
for instance, in separating surgically or otherwise injured tissue as a
means of **preventing adhesions**.

L3 ANSWER 7 OF 9 USPATFULL

ACCESSION NUMBER: 94:106318 USPATFULL
TITLE: Method for making a drug delivery balloon catheter
INVENTOR(S): Amundson, Rodney R., Lindstrom, MN, United States
Hull, Vincent W., Ham Lake, MN, United States
Dror, Michael, Edina, MN, United States
Schwartz, Robert S., Rochester, MN, United States
PATENT ASSIGNEE(S): Medtronic, Inc., Minneapolis, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5370614		19941206
APPLICATION INFO.:	US 1993-155402		19931119 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-989412, filed on 11 Dec 1992, now patented, Pat. No. US 5324261 which is a continuation-in-part of Ser. No. US 1992-853661, filed on 19 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-637436, filed on 4 Jan 1991, now patented, Pat. No. US 5102402		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rosenbaum, C. Fred		
ASSISTANT EXAMINER:	Maglione, Corrine		
LEGAL REPRESENTATIVE:	Latham, Daniel W., Patton, Harold R.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	343		

AB A balloon catheter includes a sheath surrounding the balloon, the sheath having a longitudinal line of weakness and a drug-containing viscous matrix material intermediate between the balloon and the sheath such that when the balloon is positioned and inflated in the body lumen it causes the sheath to burst at the line of weakness and release viscous matrix material onto said body lumen. The device provides accurate placement of the dosage required at the location in need of treatment. The catheter is especially useful in balloon angioplasty procedures.

L3 ANSWER 8 OF 9 USPATFULL

ACCESSION NUMBER: 94:55084 USPATFULL
TITLE: Drug delivery balloon catheter with line of weakness
INVENTOR(S): Amundson, Rodney R., Lindstrom, MN, United States
Hull, Vincent W., Ham Lake, MN, United States
Dror, Michael, Edina, MN, United States
Schwartz, Robert S., Rochester, MN, United States
PATENT ASSIGNEE(S): Medtronic, Inc., Minneapolis, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5324261		19940628
APPLICATION INFO.:	US 1992-989412		19921211 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-853661, filed on 19 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-637436, filed on 4 Jan 1991, now patented, Pat. No. US 5102402		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Kruter, Jerome L.
LEGAL REPRESENTATIVE: Latham, Daniel W., Patton, Harold R.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 353

AB A balloon catheter includes a sheath surrounding the balloon, the sheath

having a longitudinal line of weakness and a drug-containing viscous matrix material intermediate between the balloon and the sheath such that when the balloon is positioned and inflated in the body lumen it causes the sheath to burst at the line of weakness and release viscous matrix material onto said body lumen. The device provides accurate placement of the dosage required at the location in need of treatment. The catheter is especially useful in balloon angioplasty procedures.

L3 ANSWER 9 OF 9 USPATFULL

ACCESSION NUMBER: 94:48963 USPATFULL
TITLE: Medical uses of in situ formed gels
INVENTOR(S): Viegas, Tacey X., Canton, MI, United States
Reeve, Lorraine E., Dexter, MI, United States
Henry, Raymond L., Grosse Pointe Woods, MI, United States
PATENT ASSIGNEE(S): Mediventures Inc., Dearborn, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5318780		19940607
APPLICATION INFO.:	US 1991-785305		19911030 (7)
DISCLAIMER DATE:	20081210		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Dykema Gossett		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1057		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical **body cavity** or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of

a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of **preventing adhesions**.

=> logoff y